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Abstract
Genome-wide association studies (GWAS) with hundreds of z _thousands of single nucleotide polymorphisms (SNPs) are popular
strategies to reveal the genetic basis of human complex diseases. Despite many successes of GWAS, it is well recognized that
new analytical approaches have to be integrated to achieve their full potential. Starting with a list of SNPs, found to be
associated with disease in GWAS, here we propose a novel methodology to devise functionally important KEGG pathways
through the identification of genes within these pathways, where these genes are obtained from SNP analysis. Our
methodologyis based onfunctionalization ofimportant SNPstoidentify effected genesand disease related pathways. We have
tested our methodology on WTCCC Rheumatoid Arthritis (RA) dataset and identified: i) previously known RA related KEGG
pathways (e.g., Toll-like receptor signaling, Jak-STAT signaling, Antigen processing, Leukocyte transendothelial migration and
MAPKsignalingpathways);ii)additional KEGGpathways(e.g.,Pathwaysincancer,Neurotrophin signaling,Chemokinesignaling
pathways) as associated with RA. Furthermore, these newly found pathways included genes which are targets of RA-specific
drugs. Even though GWAS analysis identifies 14 out of 83 of those drug target genes; newly found functionally important KEGG
pathways led to the discovery of 25 out of 83 genes, known to be used as drug targets for the treatment of RA. Among the
previously knownpathways, weidentified additionalgenes associated withRA(e.g. Antigen processing and presentation, Tight
junction). Importantly,within these pathways, the associations betweensomeofthese additionallyfoundgenes,suchasHLA-C,
HLA-G, PRKCQ, PRKCZ, TAP1, TAP2 and RA were verified by either OMIM database or by literature retrieved from the NCBI
PubMed module.With the whole-genomesequencingonthe horizon,weshow thatthefull potentialof GWAS can beachieved
by integrating pathway and network-oriented analysis and prior knowledge from functional properties of a SNP.
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Introduction
Genome-Wide Association Studies (GWAS) – in which
hundreds of thousands of single nucleotide polymorphisms (SNPs)
are tested simultaneously in thousands of cases and controls for
association with a human complex disease - have revolutionized
the search for genetic basis of these diseases [1]. The success of
GWAS can be summarized with the published 600 genomewide
association studies covering 150 distinct diseases and traits,
explaining 800 SNP-trait associations (P,5610
28). These studies
not only identified novel common genetic risk factors, but also
confirmed the importance of previously identified genetic variants.
However, in a typical GWAS, only a minority of DNA sequence
variations that modulate disease susceptibility and their neighbor-
ing genes with the strongest evidence of association is explained.
Whereas, in this ‘‘most-significant SNPs/genes’’ approach, genetic
variants that confer a small disease risk but are of potential
biological importance are likely to be missed. Hence, it is
recognized that GWAS data is undermined in most cases and
concentrating on a few SNPs and/or genes with the strongest
evidence of disease association is not enough to exploit underlying
physiological processes and disease mechanisms [2]. For instance,
PPARG variants are known to be associated with type 2 diabetes
(T2D) [3]. Whereas, this true association is missed by the four out
of five GWA studies designed to replicate the initial finding, due to
its modest effect on disease susceptibility (odds ratio 1.2) [4,5]. A
similar situation was recently observed regarding the association of
IL7R variants with multiple sclerosis [5]. Especially in complex
diseases, which are intrinsicly multifactorial, rather than identify-
ing single genes, the identification of affected pathways would shed
light into understanding of disease development mechanism.
Pathway-based approaches thought to complement the most-
significant SNPs/genes approach and provide additional insights
into interpretation of GWAS data on complex diseases [2,5,6,7].
These pathway-based GWASs are based on the hypothesis that
multiple genes in the same biological pathway contribute to disease
etiology, wheras common variations in each of these genes make
mild contributions to disease risk. The use of prior knowledge in the
form of pathway databases is demonstrated in GWAS of diseases
such as Parkinson’s disease, age-related macular degeneration,
bipolar disorder, rheumatoid arthritis, and Crohn’s disease [8,9,10,
11,12]. While the concept of pathway analysis for GWAS is attractive,
it is restricted by our limited knowledge of cellular processes.
On the other hand, a limited number of studies have attempted
to incorporate network-based analysis to interrelate positional
candidate genes from disease loci and/or to prioritize candidate
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do not use actual genetic (genotypic) data or are applied to model
organisms. To the best of our knowledge, the only study to date
that uses both a protein interaction network and pathway analysis
to reveal significant disease related genes and pathways in genetic
association studies is conducted by Baranzini et al. [5] on Multiple
Sclerosis. Since this study is gene centered, it is possible that true
associations with markers that lie in large intergenic regions were
neglected and the analysis is limited to the known functional
properties of genes. Additionally, to improve the power in GWAS,
Roeder et al. developed a method to incorporate linkage data to
weight the association P values [17]; and a weighted multiple
testing procedure that facilitates the input of prior information in
the form of groupings of tests [18]. In this study, they have shown
that the grouped-weighting of prior information often leads to an
increase in power even if many of the groupings are not correlated
with the signal [18].
To further reduce the number of selected SNPs after a GWAS,
here we hypothesize that researchers need to integrate information
from various biological databases, where biologically significant
SNPs, such as those occurring in functional genomic regions such as
protein-coding or regulatory regions; or those located in genes
related to the phenotype are given higher priority. In this light, we
present a pathway and network oriented GWAS analysis (PA-
NOGA) that challenges to identify individually modest genetic
effects by combining nominally significant evidence of genetic
association with current knowledge of biochemical pathways,
protein-protein interaction networks, and functional and genetic
information of selected SNPs. Starting with GWAS data, our
proposed methodology assigns genes into functionally important
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways
(http://www.genome.ad.jp/kegg/pathway.html). In addition to the
network and pathway-based analysis, PANOGA incorporates a
regional score, which integrates functional properties of a SNP that
is found to be important in GWAS.
We applied our methodology on a GWAS of Rheumatoid
Arthritis (RA); and identified both previously found RA related
KEGG pathways and additional pathways. We compared our
findings with the known disease genes collected from the OMIM
database (http://www.ncbi.nlm.nih.gov/Omim), NCBI PubMed
module; RA-specific drug target genes obtained from Pharmaccoge-
nomics Knowledge Base website (http://www.pharmgkb.org/in-
dex.jsp); and with their KEGG functional enrichments. Our analysis
highlights the importance of particular genes that have already been
identified as significant in the pathogenesis of RA, gives more insights
into their potential role considering their biological pathways, and
shed light into their ability to affect neighboring pathways (presented
as functional annotation network). The strength of our methodology
stems from its multidimensional perspective, where we combine
evidence from the following 4 resources: i) Genetic association
information obtained through GWAS, ii) SNP functional informa-
tion, iii) Protein-protein interaction data, iv) Biochemical pathways.
In summary, we showed that using our technique, a GWAS can be
mined further to identify novel genes and pathways that are
associated with a specific human complex disease. In the following
sections we present our findings and identify areas for further
research. As more biological knowledge and genomic data become
publicly available, we believe that such methodological developments
will better dissect the genetic architectureof human complex diseases.
Methods
Starting with a list of SNPs, found to be associated with disease
in GWAS, we propose a novel methodology to devise the list of
genes included in a functionally important KEGG pathway. In our
study, GWAS results are used in the form of SNP rs ids vs. p-
values, where the p-values refer to the genotypic p-values of
association for each tested SNP. We only focused on SNPs with
nominal evidence of association (P,0.05) in a GWAS, following
the study in [5]. Our system proceeds in three main steps as
outlined in Figure 1. In Step 1a, SNPs are assigned to genes based
on SNP/gene transcript functional properties. In order to
incorporate functional information, a SPOT [19] and F-SNP
[20,21] Pw-values are assigned to each gene as two separate
attributes in Step 1b. This step also checks whether the input SNPs
overlap with known Transcription Factor Binding Sites (TFBS) at
TRANSFAC [22]. These functional properties are assigned as
gene attributes to a human protein protein interaction map in Step
2. Lastly, Step 3 conducts functional enrichment and assigns genes
into functionally relevant KEGG pathways. We further describe
each step below.
Step 1a: Assigning SNPs to genes
It is hypothesized that meaningful combination of genes
harboring markers with only modest evidence of association can
be identified if they belong to the same biological pathway or
mechanism [5]. Therefore, the gene and pathway-based associa-
tion analysis allows us to gain insight into the functional basis of
the association and facilitates to unravel the mechanisms of
complex diseases. However, a SNP may be associated with many
genes, i.e. it can be located in a gene with several known transcripts
due to alternative splicing, or in one gene and very close to another
gene, or at the intersection of different genes on different strands
and hence a SNP may have different functional consequences on
each transcript. To assign SNPs into genes by considering all known
SNP/gene transcript associations, our methodology uses SPOT
program [19] which selects the gene with the highest priority. To
generate those SNP/gene transcript associations, SPOT program
utilizes information from the PolyPhen method of predicting the
effect of an amino acid substitution on the properties of the protein
product.Thoseeffectscanbedirectlydetected fromDNAandRNA
sequences, like nonsense and missense amino acid substitutions,
untranslated regions, coding regions, and frameshifts. Hence, by
prioritizing all known SNP/gene transcript consequences, propi-
tious association signals found in GWAS, are not lost at the SNP to
gene transition step.
Step 1b: Regional Score Calculations for Genes
In this step, our methodology combines functional, genomic
information of a SNP with P-value of a SNP from a statistical test
for genetic association, and then transfers this weighted P-value
(Pw-value) to the SNP’s associated gene. Among many different
web tools dealing with SNP biological properties, we have decided
to combine the scores of SPOT [19] and F-SNP [20] servers. A
comprehensive comparison of those meta-tools can be found
elsewhere in literature, but notably in a review paper [25].
SPOT score [19] takes into account SNP/gene transcript
functional properties (including nonsense, frameshift, missense and
59 and 39-UTR designations), impact of an amino acid substitution
on the properties of the protein product from PolyPhen server
[26,27], evolutionary conserved regions from ECRbase [28], all
possible LD proxies - SNPs with r
2 over a predefined threshold in
a specific HapMap sample [29]. On the other hand, F-SNP score
(FS score) incorporates: functional effects of SNPs, predicted at the
splicing, transcriptional, translational and post-translational level
[20]. The details of the data sources used in our regional score can
be found in Table 1.
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26277Figure 1. Outline of our assessment process. In Step 1, a gene-wise Pw-value for association with disease was computed by integrating
functional information. In Step 2, significant Pw-values were loaded as two separate attributes of the genes in a PPI network and visualized using
Cytoscape [23]. At this step, active sub-networks of interacting gene products that were also associated with the disease, are identified using jActive
Modules plugin [24]. In Step 3, genes in an identified active sub-network were tested whether they are part of functionally important KEGG pathways.
doi:10.1371/journal.pone.0026277.g001
Table 1. Description of data sources used in our regional score.
Functional Category Tool Description Meta-tool
Protein Coding LS-SNP, SNPs3D, SIFT, SNPeffect SNP annotation tool, Impact of nsSNPs on protein function, Prediction
of amino acid substitution effects, SNP annotation with human disease
F-SNP
Protein Coding PolyPhen Prediction of amino acid substitution effects SPOT,
F-SNP
Protein Coding, Splicing Regulation,
Transcriptional Regulation
Ensembl Extensive genomic database including SNPs and gene transcripts F-SNP
Splicing Regulation ESEfinder, ESRSearch, PESX,
RescueESE
Exonic splice sites, Exonic-splicing regulatory (ESR) sequences, Exon
splicing enhancers/silencers, Exonic splice sites
F-SNP
Transcriptional Regulation Consite
TFSearch
Conserved transcription factor binding sites,
Transcription factor binding sites
F-SNP
Transcriptional Regulation SNPnexus Conserved transcription factor binding sites SNPnexus
Transcriptional Regulation,
Conserved Region
GoldenPath MicroRNA, cpgIslands, evolutionary conserved regions F-SNP
Conserved Region ECRBase Evolutionary conserved regions SPOT
Post-translation KinasePhos, OGPET, Sulfinator Phosphorylation sites, Prediction of O-glycosylation sites in proteins,
Tyrosine sulfination sites
F-SNP
Genomic Coordinates dbSNP General SNP/gene transcript properties SPOT
Genomic Coordinates UCSC Extensive genomic database including SNPs and gene transcripts F-SNP
LD estimation HapMap,
Haploview
Dense genotyping on multiple populations, useful for LD estimates
Estimation of r
2 LD coefficients for each population
SPOT
doi:10.1371/journal.pone.0026277.t001
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association, the following scoring scheme is proposed in [30]. In
[30], firstly, a non-negative prioritization score (PS) was specified for
each SNP and then, the weighted P-value Pw is defined by Pw=P/
10
PS [17,30], where P denotes GWAS p-value for a particular SNP.
In this scheme, smaller values of Pw indicate higher priority.
Following this convention, we have calculated SPOT Pw-value
using SPOT prioritization score and F-SNP Pw-value using F-SNP
prioritization score. Since SNPs are associated with genes in Step 1a
of our method, these two weighted p-values (Pw-values) are
automatically transferred into the SNP’s associated gene as two
separate attributes. Henceeachgene has a SPOT Pw-valueand a F-
SNP Pw-value for association with RA (gene-wise Pw-values). If
morethan one SNPisassigned tothe same gene inStep1a,the SNP
with the lowest weighted p-value (Pw) is chosen and assigned to the
gene. In other words, the SPOT Pw-value of a gene is calculated as
the lowest SPOT Pw-value of the SNP that is assigned to that
particular gene among all the SPOT Pw-values of the SNPs
assigned to the same gene. Same is true for F-SNP Pw-value.
Lastly, SNPnexus [31] checks for possible overlap of a SNP with
conserved TFBSs from TRANSFAC Matrix Database (v.7.0, [22])
and returns the related TF name. If this TF is not already found in
Step 1a, this TF is added to our list by transferring its SPOT and
F-SNP Pw-values from its associated SNP.
Step 2: Active sub-network searches
By using the regional scores, calculated in the previous step for
the genes, this step aims to find out active sub-networks in the
human PPI network. Firstly, a human PPI network was imported
into Cytoscape [23]. Secondly, regional scores (SPOT and F-SNP
Pw-values) were loaded as attributes of the genes in this network.
Lastly, active sub-networks of interacting gene products that were
possibly associated with the disease are identified using jActive
Modules [24,32] in a formal way. Basicly, jActive Modules [24] is
a Cytoscape plugin to identify active sub-networks via incorpo-
rating both the topological properties of a PPI network and the
attributes of the nodes (proteins). In this approach, firstly the
attributes (SPOT and F-SNP Pw-values) are mapped into biological
networks, secondly a statistical measure (as explained below) is used
to score sub-networks based on the attributes, and finally a search
algorithm is used to find active sub-networks with high score.
Biologically speaking, an active sub-network (statistically
significant module) is a sub-network in our PPI network that the
protein products of this set of genes – probably associated to the
disease- also physically interact, thus raises the possibility that they
belong to the same pathway or biological process. To rate the
biological activity of a particular sub-network, jActive Modules
starts by assessing the significance of differential association with
disease for each gene (by comparing the gene-wise Pw-values of
association with the disease). In this procedure, jActive Module
samples p-values from the distribution of p-values loaded into
Cytoscape, and not from a normal uniform distribution. Then, a
network is generated from each node by systematically adding one
neighbor at a time. The aggregate z-score (S) of an entire sub-
network, consisting of k genes is calculated via summing the scores
of all genes zi in the sub-network and then dividing by the square-
root of k. To extend the z-score over multiple conditions
(attributes), jActive Module sorts z-scores for each attribute,
adjusts for rank, maximum score is corrected using the
background score distribution [24]. The scoring system of jActive
Modules ensures that the expected mean and variance of the
subgraph scores are independent of subgraph size [24]. jActive
Modules plugin also corrects for the fact that a bigger sub-network
is more likely to contain nodes with significant p-values by random
chance [24]. When S stops to increase, the sub-network stops
growing and is reported as a module. Next, the test statistic (S) is
compared with an appropriate background distribution to
properly capture the connection between network topology and
association with disease. As a background distribution, we used the
scores of sub-networks randomly selected from the entire human
PPI network, as provided by jActive Modules. In order to make
the background distribution independent of the module size,
jActive Modules creates a background distribution by scoring
10,000 random sub-networks of each size in a Monte Carlo
procedure. In our study, modules with S.3 were reported as
significant (active sub-network), as stated in the original publica-
tion. The sub-network with the highest score is selected for further
functional enrichment.
Step 3: Functional Enrichment of the Sub-networks
Next step following the identification of sub-networks is to
evaluate whether these sub-networks were biologically meaningful.
Our methodology has a functional enrichment component that
computes the proportion of the genes in an identified sub-network
that are also found in a specific human biochemical pathway,
compared to the overall proportion of genes described for that
pathway. For this purpose, ClueGO plugin of Cytoscape [33] is
utilized in this step. ClueGO is an open-source Java tool that
extracts the non-redundant biological information for groups of
genes using GO, KEGG and BioCarta ontologies [33]. Unlike
other functional enrichment analysis tools [34,35,36,37,38] that
present their results as long lists or complex hierarchical trees;
ClueGO facilitates the biological interpratation via visualizing
functionally grouped terms in the form of networks and charts
[33]. To link the terms in the network, ClueGO uses kappa
statistics, in a similar way as described in [35]. Among different
ontologies, since KEGG database primarily categorizes genes into
bona-fide biological pathways; and since biological interpretation
of pathways is more straightforward compared to GO terms, we
report only our functional enrichment results using KEGG
pathways. To determine the statistical significance of an
enrichment of the identified sub-network, two-sided (Enrich-
ment/Depletion) test based on the hypergeometric distribution is
used in our methodology. To correct the P-values for multiple
testing, Bonferroni correction method is applied.
Experiments
Rheumatoid Arthritis (RA, OMIM # 180300) is a systemic
inflammatory disease, primarily affecting synovial joints. As
reported at the 2008 American College of Rheumatology meeting,
about 1% of the world’s population is afflicted by RA and women
affected three times more often than men. Disease onset is most
frequent between the ages of 40 and 50, but people of any age can
be affected. While the earlier stages of the disease appear a
disabling and painful condition, in the later stages it can lead to
substantial loss of functioning and mobility.
Being a complex disease, the etiology of RA depends on a
combination of multiple genetic and environmental conditions,
involving a yet unknown number of genes. The heritability of this
disease is estimated as ,50% based on family studies, including
twin studies [39,40]. In GWASs among RA patients of European
ancestry, multiple risk alleles have been identified in the major
histocompatibility complex (MHC) region, and 25 RA risk alleles
have been confirmed in 23 non-MHC loci [41,42,43,44,45,
46,47,48,49,50,51]. These variants explain about 23% of the
genetic burden of RA [41], indicating that additional variations
remain to be discovered to explain the polygenic etiology of RA.
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We have applied our methodology on Wellcome Trust Case
Control Consortium (WTCCC) Rheumatoid Arthritis (RA)
dataset, in which 500,475 SNPs were tested on 5003 samples
(1999 cases and 3004 controls) using Affymetrix GeneChip
Human Mapping 500 K Array Set. SNP data and the genotypic
P-values of association for each tested SNP were downloaded from
the WTCCC project webpage (www.wtccc.org.uk). In total,
25,027 SNPs were included from WTCCC dataset, showing
nominal evidence of association (P,0.05).
Protein-protein interaction (PPI) data
A human protein-protein interaction (PPI) data was obtained
from the supplementary material of Goh et al. ’s study [52]. This
dataset is composed of two high quality systematic yeast two-
hybrid experiments [53,54] and PPIs obtained from literature by
manual curation [53]. The integrated set of PPIs contains 61,070
interactions between 10,174 genes (22,052 non-self-interacting,
non-redundant interactions).
Results
Starting with 25,176 SNPs, that are found to be significant in a
GWAS (WTCCC RA dataset), PANOGA was performed to
identify RA related genes and functionally important KEGG
pathways. These SNPs were assigned into 4,029 genes using
SPOT webserver [19] by considering all known SNP/gene
transcript associations. As the possible overlap of a SNP with
conserved TFBSs was considered, by using SNPnexus program
[31], we incorporated 65 more proteins (TFs) that bind to the
TFBS, that an RA associated SNP resides in. In order to
incorporate functional information (regional score) to these genes,
SPOT and F-SNP Pw-values were calculated as mentioned in the
methods section. Following these calculations, network oriented
steps of the PANOGA was realized using Cytoscape [23]. SPOT
and F-SNP Pw-values were used as attributes of the nodes (4094
genes) in the curated PPI network. We next searched for active
sub-networks using the Cytoscape plugin jActive Modules. This
plugin combines the network topology with attributes (SPOT and
F-SNP Pw-values in our case) of each gene to extract potentially
meaningful sub-networks. The higher the assigned aggregate z-
score of a sub-network is, biologically more active the sub-network
is. As in the original publication of jActive Modules [24], sub-
networks with a score S.3 (3 SD above the mean of randomized
scores) were considered significant. Hence, our results with scores
around 16 showed that this sub-network is statistically significant.
But the involvement of the genes in this network with RA is further
investigated through comparison with existing RA related
information in databases.
Significant sub-networks for RA
Using both GWAS p-values and regional score, we identified 5
significant sub-networks on the basis of their aggregate degree of
genetic association with RA. Due to the nature of the search
algorithm, several of these sub-networks overlap extensively in their
component genes. Thus, to describe a sub-network representative of
associationwithRA,weselected theone with the highestscore.This
selected active sub-network is composed of 275 genes (our gene set)
and 778 edges, as shown in Figure 2a. Associations between 20
genes from this sub-network (XCL1, VCAM1, TRPV1, TRPC1,
SPP1, RUNX1, RAC1, PRKCZ, NR3C1, NFKB1, MAP2K4,
JUN, ITGB1, ITGAV, HMGB1, HLA-DMB, HLA-C, ERBB2,
EPAS1, CCL21) and RA were verified by literature retrieved from
the NCBI PubMed module and OMIM, as shown in Figure 2b.
Next, we checked the topological parameters of this network.
The distribution of the number of links per node (degree
distribution, P(k)) is an important measure for a network to decide
if it is a random, scale-free or hierarchical network. As shown in
Figure 3a, the degree distribution of our highest scoring sub-
network follows a power-law distribution (P(k)=ax
2c, a=120.03,
c=1.353, R
2=0.773, Correlation=0.891 in log log scale) and
hence it is scale-free, as expected from a biological network
[55,56,57,58]. The unusual properties of scale-free networks are
valid only for c,3 and the smaller the value of c, the more
important the role of the hubs is in the network [59]. Similar to the
degree distribution of the main PPI network (c=1.617), the degree
distribution of other top 5-scored sub-networks follows a power-law
distribution (c=1.418, 1.365, 1.406, 1.330). We also randomized
our highest scoring sub-network using Erdos-Renyi algorithm and
observed that its node degree distribution follows a Poisson
distribution as expected from a random network (Figure 3b).
Functionally important KEGG pathways for RA
As a result of the functional enrichment step (Step 3) of our
methodology, we identified 87 KEGG pathway terms. In Table 2,
we represent 20 most significant pathways (determined by their p-
values), which are mostly related to immunity and inflammation,
cell adhesion and cancers. Most of these pathways (Chemokine
signaling, Neurotrophin signaling, Pathways in cancer, Leukocyte
transendothelial migration, T cell receptor signaling, Toll-like
receptor signaling, Allograft rejection, MAPK signaling, Apopto-
sis, Jak-STAT signaling) have been previously found to be
associated with RA experimentally. In Table 2, we formatted
the pathways and genes in italic, bold, both italic and bold,
respectively, if they are computationally found only, experimen-
tally found only, or found both experimentally and computation-
ally. For example, Toll-like receptor (TLR) signaling pathway term
was formatted in both italic and bold since other computational
methods identified this term and it is also experimentally known to
play an important role in the development and progress of RA.
Among the most significant pathways identified by our method-
ology are Focal Adhesion and Cell Adhesion Molecules (CAM)
pathways. These pathways are experimentally shown to play a
critical role in cellular processes such as osteoclass pathology and
angiogenesis, which are known to be important for RA [60].
We compared our findings with previously found RA related
KEGG pathways and with the genes found from those pathways.
Wu et al. [61], created a comprehensive molecular interaction
map for RA by combining the molecules and pathways found to
be associated with RA based on merging all available papers
related to high throughput experiments on RA. Following a
procedure as in [62], they have decomposed their network into 11
modules using the Cytoscape plugin BiNoM [63]. DAVID [35]
pathway analysis on their largest module with 292 nodes for 104
proteins and 334 edges returned 26 different KEGG pathways. In
summary, this module contains 43 proteins from the MAPK
signaling pathway, 36 proteins from focal adhesion, 23 proteins
from the ErbB signaling pathway, and some cancer associated
pathways such as leukemia, prostate cancer and colorectal cancer.
In another study by Martin et al., 2010, the genomic regions
showing low-significance associations in previous GWAS of RA
(WTCCC and NARAC datasets) were further explored. Using
Prioritizer software [13], they have prioritised genes from similar
pathways but located in different regions. This tool searches for
those genes belonging to the same biological pathways or related
biological pathways, based on the assumption that true disease-
causing genes are functionally related. Prioritizer software uses a
Bayesian approach to reconstruct a functional gene network based
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the KEGG. Martin et al., 2010 reported 18 overrepresented
KEGG pathways; in which Jak-STAT signaling pathway, Glioma,
Calcium signaling pathway, Long-term potentiation, Apoptosis
had the top 5 scores.
Baranzini et al., 2009 conducted a pathway-oriented analysis on
WTCCC GWAS data for RA and another GWAS data by Plenge
and collaborators. 9 KEGG pathways were identified in this study
including Cell adhesion molecules (CAMs), Antigen processing
and presentation, Type I diabetes mellitus. Lastly, the screening
Figure 2. The highest scoring sub-network. a. This sub-network is composed of 275 nodes and 778 edges (as found in Step 2 of PANOGA).
Node size is shown as proportional to the degree of a node. b. Zoomed in view of the highest scoring sub-network. 20 genes known in literature as
associated with RA are shown in green. Blue denotes the genes in our highest scoring sub-network that cannot be associated with RA in literature.
doi:10.1371/journal.pone.0026277.g002
Figure 3. Node degree distributions of our highest scoring sub-network vs. random network. a. Our sub-network follows a power-law
(P(k)=ax
2c, a=120.03, c=1.353, R
2=0.773, Correlation=0.891 in log log scale), showing that our network displays scale-free properties, as expected
from a biological network. b. The random network is obtained via randomization of our highest scoring sub-network using Erdos-Renyi algorithm.
doi:10.1371/journal.pone.0026277.g003
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GWAS data considers all SNPs with nominal evidence of Bayesian
association, structural and functional similarities of corresponding
genes. Responsible pathways identified in their study include Jak-
STAT signaling pathways, cell adhesion molecules, and MAPK
signaling pathways.
Comparative results with these three studies are shown in
Table 3 in terms of number of genes found in commonly identified
KEGG pathways. While most of these associations are computa-
tional predictions only, the functional relations of five of these
pathways (Jak-STAT signalling, apoptosis, T cell receptor signal-
ling, leukocyte transendothelial migration and cytokine-cytokine
receptorinteraction)with RApathogenesisareknown[42,46].Also,
the effect of Toll-like receptor (TLR) signaling pathway and MAPK
signaling pathway on RA is known. Here it is important to note that
these associations are obtained by different methods on different
datasets. For example, while Wu et al. utilizes text-mining [61],
Martin et al. mines GWAS data from WTCCC and NARAC
studies (including variations on more cases and controls) [64], and
Zhang et al. applies their methodology on GAW16 (Genetic
Analysis Workshop) data [65]. PANOGA identifies previously
found KEGG pathway terms with high statistical significance
(terms shown in italic format for former computational identifica-
tion, in italic and bold for both computational and experimental
identification).
From those previously identified pathways, we identified
additional genes associated with RA within some of these path-
ways (e.g. Antigen processing and presentation, Tight junction).
Table 2. Overrepresented KEGG Pathways found in the highest scoring sub-network as associated with RA.
KEGG Term
Num. of
Genes
Found
Asso-
ciated
Genes (%)
Term
Pvalue Corr.
w/Bonfer. Associated Genes Found
Focal adhesion 30 14,9 9,33E-11 ACTB, ACTG1, AKT1, COL4A4, CRKL, CTNNB1, EGF, EGFR, FLNA, FLNB, FLT4, FYN, GRLF1,
ITGA5, ITGB1, ITGB3, ITGB5, MAP2K1, PAK4, PIK3R2, PTK2, RAC1, RHOA, SHC3, SRC, VASP,
VAV1, VAV3, VTN, ZYX
ErbB signaling pathway 20 22,9 2,13E-10 AKT1, CAMK2D, CAMK2G, CBL, CRKL, EGF, EGFR, ERBB3, ERBB4, HBEGF, KRAS, MAP2K1, NCK2,
NRG1, PAK4, PIK3R2, PTK2, SHC3, SRC, STAT5A
Tight junction 22 16,4 1,80E-08 ACTG1, ACTN2, CASK, CTNNB1, EPB41L1, EPB41L2, EPB41L3, GNAI1, INADL, KRAS, LLGL1,
MAGI1, MAGI3, PARD3, PRKCE, PRKCI, PRKCQ, PRKCZ, RHOA, SPTAN1, SRC, TJP1
Chemokine signaling
pathway
26 13,7 2,31E-08 ADCY2, ADCY5, ADCY8, AKT1, CHUK, CRKL, DOCK2, ELMO1, FGR, GNG2, IKBKB, KRAS,
MAP2K1, NCF1, PARD3, PIK3R2, PRKCZ, PTK2, PTK2B, RAC1, RHOA, SHC3, STAT3, TIAM1,
VAV1, VAV3
Adherens junction 17 22,6 1,16E-07 ACTB, BAIAP2, CREBBP, CTNNB1, EP300, FYN, PARD3, PTPRF, PTPRM, RHOA, SMAD2, SMAD4,
SORBS1, SRC, TCF7L2, TGFBR1, TJP1
Bacterial invasion of
epithelial cells
15 20,5 1,57E-07 ACTB, ACTG1, CBL, CLTC, CTNNB1, CTTN, DNM3, ELMO1, ITGB1, PIK3R1,P T K 2 ,RAC1, RHOA,
SRC, WASL
Neurotrophin signaling
pathway
20 15,8 2,36E-07 ARHGDIB, CALM1, CALM3, CAMK2D, IKBKB, IRS1, JUN, KRAS, MAPK10, MAPK3, NFKB1, NTRK1,
NTRK3, PLCG1, RAC1, RHOA, RPS6KA1, TP73, YWHAE, YWHAH
Long-term potentiation 15 21,4 3,67E-07 ADCY8, CALM1, CALM3, CAMK2D, EP300, GRIA1, GRIN1, GRIN2B, GRM5, ITPR1, ITPR3, KRAS,
MAPK3, PPP1CB, RPS6KA1
Pathways in cancer 32 9,7 1,12E-06 CASP8, CBL, CHUK, COL4A4, CTNNB1, EP300, EPAS1, ERBB2, FOXO1, FZD4, IKBKB, ITGAV,
ITGB1, JUN, KIT, KRAS, MAPK10, MAPK3, NFKB1, NTRK1, PIAS1, PIAS2, PLCG1, PTK2, RAC1,
RHOA, RUNX1, SMAD4, STAT1, STAT5A, TCF7L2, TPM3
Chronic myeloid leukemia 14 19,1 1,44E-06 CBL, CRK, CRKL, HRAS, IKBKB, MAPK3, NFKB1, PIK3R2, SHC1, SMAD3, SMAD4, SOS1, STAT5B,
TGFBR1
Cell adhesion molecules
(CAMs)
18 13,2 1,42E-05 CD226, CD28, CD4, CDH2, HLA-B, HLA-C, HLA-DMB, HLA-DPA1, HLA-DQA2, HLA-DRA,
ITGB1, L1CAM, NCAM1, NLGN1, PTPRC, PTPRF, PTPRM, SDC3
Leukocyte transendothelial
migration
17 11 1,72E-05 ACTG1, ACTN2, CTNNB1, EZR, GNAI1, GRLF1, ITGB1, NCF1, PLCG1, PTK2, PTK2B, RAC1,
RHOA, TXK, VAV1, VAV3, VCAM1
T cell receptor signaling
pathway
16 14,8 2,70E-05 CBL, CD247, CD28, CD4, CHUK, FYN, HRAS, IKBKB, LCK, MAP2K1, NCK2, PLCG1, PRKCQ,
PTPRC, RHOA, VAV3
Toll-like receptor signaling
pathway
13 12,7 1,97E-03 CASP8, CHUK, IFNAR1, IFNAR2, IKBKB, JUN, MAP2K4, MAPK10, MAPK3, NFKB1, RAC1, SPP1,
STAT1
Antigen processing and
presentation
11 13,9 2,08E-03 CALR, CANX, HLA-B, HLA-C, HLA-DMB, HLA-DRA, HLA-F, HLA-G, HSPA1L, TAP1, TAP2
Allograft rejection 8 20 2,16E-03 CD28, HLA-B, HLA-C, HLA-DMB, HLA-DPA1, HLA-DQA2, HLA-DRA, IL12A
MAPK signaling pathway 20 7,4 6,13E-03 CACNA1A, CHUK, CRKL, DAXX, EGF, FLNA, FLNB, FOS, HRAS, HSPA1L, JUN, MAPK10, MAPK3,
MAPK8, NF1, RAC1, RPS6KA1, RRAS2, SOS1, TGFBR1
Type I diabetes mellitus 8 17,3 6,24E-03 CD28, HLA-B, HLA-C, HLA-DMB, HLA-DPA1, HLA-DQA2, HLA-DRA, IL12A
Apoptosis 11 12,5 6,84E-03 CAPN1, CASP10, CASP8, CHUK, CSF2RB, FADD, IKBKB, IRAK1, IRAK4, PRKAR2A, PRKAR2B
Jak-STAT signaling pathway 15 9,6 7,41E-03 CBL, CREBBP, CSF2RB, EP300, IFNAR1, IFNAR2, IL12A, IL2RA, IL2RB, JAK1, LIFR, SOCS5, STAT1,
STAT3, STAT5A
Bold formatting denotes experimentally verified RA associated genes and pathways, italic formatting denotes computationally found, RA associated genes and
pathways, bold and italic formatting denotes both experimental and computational verification regarding susceptibility to RA.
doi:10.1371/journal.pone.0026277.t002
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of these additionally found genes, such as HLA-C, HLA-G,
PRKCQ, PRKCZ, TAP1, TAP2 (formatted in bold in Table 2)
andRAwerealsoverifiedbyeitherOMIMdatabaseorbyliterature
retrieved from the NCBI PubMed module.
Different from previous studies, we also identified Chemokine
signaling, Neurotrophin signaling, Pathways in Cancer, Allograft
rejection pathways as significant for RA. While the significance of
these pathways in relation to RA were not thoroughly discussed in
literature, the KEGG functional enrichment of RA-specific drug
target genes, included these terms (whole list of drug target genes
for RA, downloaded from Pharmaccogenomics Knowledge Base
website and whole list of the KEGG functional enrichment of
these genes can be found in Supplementary Tables S1 and S2,
respectively). In this database, 83 genes are associated with drugs
that are used to treat RA. Furthermore, within these pathways, the
associations between some of the genes, such as EPAS1, CD28,
HLA-C (formatted in bold in Table 2) and RA were verified by
either OMIM database or by literature retrieved from the NCBI
PubMed module.
In order to assess the contribution of the found pathways and
associated genes to disease mechanism, we also searched all
identified genesfrom all found pathwaysinthePharmaccogenomics
Knowledge Base website. When we filtered SNPs based on their
significanceinGWAS(p-value ,0.05cutoffis applied) andassigned
into genes, 14 out of 85 drug target genes were found. Whereas, via
considering all the genes in the found KEGG pathways, we
identified 25outof85drugtargetgenesassociatedwithRA(listed in
Supplementary Table S3). Hence, we showed that incorporating
pathway knowledge on top of GWASs provides additional insights
into the pathogenesis of RA.
To emphasize the effect of the regional score in PANOGA, we
have applied our analysis on 4,094 genes firstly by using only
GWAS p-values, secondly by using both SPOT and F-SNP Pw-
values as attributes. As can be seen in Table 3, (PANOGA (w/
regional scores) column vs. PANOGA (only GWAS pvalues)
column), incorporating functional information of a SNP increases
the number of genes identified as associated with RA; and hence
increases the significance of the identified KEGG pathway term.
Functionally grouped annotation network of RA
The diversity and complexity of the identified KEGG pathways
involved in one sub-network confirms that RA is a complex
systemic disease. Since a gene can be present in multiple pathways,
we would like to show the pathway relationship, based on whether
the pathways are sharing same genes. Hence, we generated a
Table 3. Comparison of found KEGG pathways with previous studies in terms of number of genes associated within each KEGG
term.
KEGG Term Number of Genes Found
Term Pvalue
Corrected Bonfer-roni
Baranzini
et.al.
Martin
et.al.
Wu
et.al
Zhang
et.al.
PANOGA (only
GWAS p-values)
PANOGA (w/2 attributes
SPOT Pw and F-SNP Pw)
Focal adhesion 0 0 36 32 22 30 9,33E-11
ErbB signaling pathway 0 0 23 0 18 20 2,13E-10
Tight junction 0 0 0 5 20 22 1,80E-008
Chemokine signaling pathway 0 0 0 0 24 26 2,31E-08
Adherens junction 0 0 0 18 16 17 1,16E-07
Bacterial invasion of epithelial cells 0 0 0 0 15 16 1,57E-007
Neurotrophin signaling pathway 0 0 0 0 20 20 2,36E-07
Long-term potentiation 0 22 0 7 14 15 3,67E-07
Pathways in cancer 0 0 0 0 29 32 1,12E-06
Chronic myeloid leukemia 4 0 21 18 10 14 1,44E-06
Cell adhesion molecules (CAMs) 8 26 0 10 12 18 1,42E-05
Leukocyte transendothelial migration 0 24 14 0 17 17 1,72E-05
T cell receptor signaling pathway 4 21 16 16 13 16 2,70E-05
Toll-like receptor signaling pathway 0 0 22 6 7 13 1,97E-03
Antigen processing and presentation 6 0 0 3 11 11 2,08E-03
Allograft rejection 0 0 0 0 8 8 2,16E-03
MAPK signaling pathway 0 0 43 34 16 20 6,13E-03
Type I diabetes mellitus 5 0 0 1 8 8 6,24E-03
Apoptosis 0 18 12 11 6 11 6,84E-03
Jak-STAT signaling pathway 0 25 0 16 13 15 7,41E-03
Prostate cancer 0 0 22 0 10 11 5,04E-02
Calcium signaling pathway 0 35 0 4 15 16 1,63E-01
VEGF signaling pathway 3 0 15 13 8 9 2,71E-01
Total 30 171 224 194 332 385
Italic formatting denotes computationally found pathways, bold formatting denotes experimentally verified RA associated pathways, bold and italic formatting denotes
both experimental and computational verification.
doi:10.1371/journal.pone.0026277.t003
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using ClueGO plugin [33]. While the nodes in a functionally
grouped network in Figure 4 denoted the found KEGG terms
associated to RA, the edges were drawn based on the existence of
shared genes using kappa statistics, in a similar way as described in
[35]. 87 pathway terms that were found to be RA associated in our
analysis were clustered into 9 groups, as can be seen in Figure 4
(according to their kappa scores) and the pathways in the same
group were shown in same color. ClueGO also assigns the most
significant pathway terms with the lowest term p-value (corrected
with Bonferroni) as group leading terms. For our functional
annotation network, Focal adhesion, Adherens junction, Chemo-
kine signaling pathways, T cell receptor signaling, Jak-STAT
signalingwereselectedas groupleadingterms,as shown inFigure5.
Indeed, these group leading terms were either experimentally or
computationally found to be related with RA, as can be seen in
Table 2. This experiment generated the interconnections between
the pathways that were found to be related with RA in our analysis.
To further check for the biological significance of our results, we
compared the functional enrichments of the genes found in the
highest scoring active sub-network with the functional enrichments
of previously determined 331 genes verified by either OMIM
database or by literature retrieved from the NCBI PubMed
module to be associated with RA [61]. While our highest scoring
sub-network with 275 genes enriched for 87 KEGG pathways,
these 331 genes mapped to 88 pathways. Among those, 37
pathways were found in common, showing significant overlap
between pathways coming from our study and the literature. In
Figure 6a, the different proportion of the genes found in KEGG
pathways from two sets was represented with a color gradient from
green for literature verified RA genes, to red for our gene set.
White denoted the pathways found in both sets with equal number
of genes. As shown in Figure 6b (the zoomed in view), Pathways in
cancer, T cell receptor signaling pathway, MAPK signaling
pathway were found in both sets with the contribution of equal
number of genes (shown in white). Whereas, the light green color
in Neurotrophin signaling pathway term indicated that although
most of the RA associated genes in this pathway comes from
literature verified set, some of the genes in our gene set were
assigned to this pathway.
Discussion
Many reports of the genome wide associaton studies emerging
in the literature, and the online GWAS catalog (http://www.
genome.gov/26525384), including 273 published GWAS so far by
National Human Genome Research Institute (NHGRI), are the
clear evidences of the success of GWAS. Unfortunately, using the
traditional approaches in GWAS, only the strongest associations
can be detected; and there are many more SNPs/genes still to be
found as associated with disease [66,67]. Lately, several GWAS
[8,9,10,11,12]haveproposed theuseof priorknowledgein the form
of pathway databases, such as the KEGG and Biocarta, or gene
ontology databases. On the other hand, Franke et al. [13] suggested
the use of protein interaction network information along with
pathway-based analysis. For Multiple Sclerosis GWAS data,
Baranzini et al. [5] demonstrated the utility of network-based
analysis. On top of these pathway and network based analyses of
GWAS, here we devised a methodology that also integrates the
functional information of a SNP as a third component. As a result
of this multidimensional screening approach, our methodology
generated a comprehensive list of functionally important KEGG
pathways for RA (Table 2). While most of these associations can be
thought ascomputationalpredictions,thefunctionalrelationsoffive
of these pathways (Jak-STAT signalling, apoptosis, T cell receptor
signalling, leukocyte transendothelial migration and cytokine-cytokine
Figure 4. Functionally grouped annotation network of our highest scoring sub-network. The relationships between the KEGG terms
(nodes) were based on the similarity of their associated genes. The size of the nodes reflected the statistical significance of the terms (term p-values
corrected with Bonferroni). Edges represent the existence of shared genes. The thickness of the edges is proportional to the number of genes shared
and calculated using kappa statistics, in a similar way as described in [35]. The grouped terms (according to their kappa scores) were shown in same
color.
doi:10.1371/journal.pone.0026277.g004
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by Raychaudhuri and Plenge et al. [41,42,46].
Additionally, the effect of Toll-like receptor (TLR) signaling
pathway and MAPK signaling pathway on RA is known as
following: TLRs are membrane-bound receptors which are
expressed in innate immune cells, such as macrophages and
dendritic cells. TLRs signaling plays an important role in the
activation and direction of the adaptive immune system by the up-
regulation of co-stimulatory molecules of antigen presenting cells.
The activation of the TLRs signaling pathway can trigger the
Figure 5. Zoomed in view of the entire functional annotation network. The most significant pathway term of the group with the lowest
term p-value (the group leading term) was shown in bold using the group specific color.
doi:10.1371/journal.pone.0026277.g005
Figure 6. Comparison of KEGG pathway terms with literature verified RA genes/our gene set were shown in green/red, respectively.
Nodes represent the identified pathway terms from any one of the two sets. The color gradient showed the gene proportion of each set associated
with the term. White color represented equal proportions from the two comparison sets. The size of the nodes reflected the statistical significance of
the terms (term p-values corrected with Bonferroni). Following the convention in Figure 4, edges represented the existence of the shared genes
between the pathway terms and node border colors mapped to the group colors. Zoomed in view of panel a is shown in panel b.
doi:10.1371/journal.pone.0026277.g006
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emerging that certain TLRs play a role in the pathogenesis of
infectious and/or infammatory diseases. There is considerable
evidence from rodent models that activation of the TLRs can
induce or exacerbate inflammatory arthritis [68].
The role of MAPK signaling pathway in the development and
progress of RA was shown to be related to cartilage damage, which
is a hallmark of RA. Cartilage damage is based on increased
proteoglycan loss as well as attachment and invasion of inflam-
matory tissue into the cartilage, which leads to its structural
disintegration. Production of matrix metalloproteinases (MMPs)
by synovial tissue appears to be a key prerequisite for synovial
tissue to invade and destroy cartilage. MAPK is a crucial signal
transduction pathway for inflammation and carries information
about inflammatory stimuli to the cell nucleus. Synthesis of MMPs
is regulated through multiple MAPK families, suggesting that a
blockade of MAPK might have structural benefit in arthritis
[43,69]. Also, activation of stress kinase pathways ERK, JNK, and
p38 MAPK is a typical feature of chronic synovitis during RA, and
several proinflammatory mediators use the signaling of these stress
kinase pathways [70].
Cytokine-cytokine receptor interaction pathway has been
previously identified by two other studies as RA associated and
included in the KEGG functional enrichment of known disease
genes [64,65]. Even though this term has not been found as
significant in our highest scoring sub-network, it has been
identified in the functional enrichment of our third highest scoring
sub-network. Due to the nature of the search algorithm used by
jActive Modules, several of the identified sub-networks overlap
extensively in their component genes. Since it is complicated and
cumbersome to represent the enrichment analysis of all identified
sub-networks, here we have shown only the results from our
highest scoring sub-network. In future, we aim to visualize the
KEGG enrichment analysis results from all identified 5 top scoring
sub-networks in a comprehensive manner.
To test whether the identified KEGG pathways could be
obtained by chance, we tested the enrichment in KEGG pathways
for 100 randomly generated networks of size 275. The enrichment
of these 100 random networks returned 68 different KEGG
pathways. Among those 68 pathways, only two of the KEGG
pathways (Type I diabetes mellitus and Allograft rejection) overlap
with the pathways shown in the Tables 2 and 3. However, the
statistical significance of these pathways were low (term p-
values=0,013 and 0,007 respectively). These two pathways are
found only for one random network out of 100 randomly
generated networks and both pathways are found due to the
existence of the following 5 random genes in this network, i.e.
PRF1, HLA-B, FAS, HLA-DQA1, IL2. Whereas in our pathway
analysis (as shown in Table 2), more genes are identified as part of
Type I diabetes mellitus and Allograft rejection pathways (i.e.
CD28, HLA-B, HLA-C, HLA-DMB, HLA-DPA1, HLA-DQA2,
HLA-DRA, IL12A). Hence, our gene list includes different genes
compared to the ones found in random network with higher
significance (term p-values=6,24E-03 and 2,16E-03 respectively).
The detailed result of this experiment can be found in
Supplementary Table S4.
Since only a couple of KEGG pathways are known to be
associated with RA in literature, for verification purposes we also
compared the genes as part of these pathways with the drug target
genes of RA in Pharmaccogenomics Knowledge Base. To this end,
we tried to find out whether taking the genes in pathway context
would enhance the results of GWA study by identifying additional
target genes. As result of assigning SNPs coming from GWAS to
genes we identified 4094 genes. Only 14 of them were mapped to
83 RA specific drug target genes. Following the application of our
method, we identified KEGG pathways that are affected by the
SNPs, and these pathways contained 25 out of 83 RA specific drug
target genes (listed in Supplementary Table S3). This provided an
added value to GWAS analysis showing that not only the genes
affected by the SNPs may be the drug targets but also other genes
in these affected pathways may also be the drug targets, as shown
by 11 extra genes identified. The analysis of SNP affected genes in
a pathway context provides added value in identification of
potential drug targets.
It is noteworthy to mention that pathway-based analyses, like it
is presented here, are limited to our knowledge of cellular
processes. The biological functions of most of the genes in the
genome are not known. Since network and pathway tools make
use of functional information from gene and protein databases,
they are biased toward the well-studied genes, interactions, and
pathways. Also, variants associated to genes not represented in the
protein-protein interaction network were not evaluated in this
analysis. Nevertheless, there is scope for the development of
related methodologies to increase the power to detect associations
in these genes. By combining information from several sources
(functional properties of SNPs, genetic association of a SNP with
the disease, PPI network), as shown in this paper, such limitations
can be overcome. We also would like to point out that our method
is not intended to be used for tag SNPs which are associated with a
specific phenotype. As a future work, we plan to fully automate our
method and convert to a webserver such that takes GWAS data as
an input and generates disease specific pathway terms.
In summary, in this article we described a network and
pathway-oriented analysis of GWAS data that also incorporates
functional features of a SNP. In order to determine the biological
significance of our results, we compared our findings with RA
associated gene list obtained from OMIM database, or retrieved
from literature using the NCBI PubMed module, or downloaded
from Pharmaccogenomics Knowledge Base website. The main
contributions of this paper can be summarized as follows:
1. We present a novel pathway and network oriented GWAS
analysis that challenges to identify disease associated KEGG
pathways by combining nominally significant evidence of
genetic association with current knowledge of biochemical
pathways, protein-protein interaction networks, and functional
information of selected SNPs.
2. We identified additional KEGG pathways (e.g. Pathways in
cancer, Neurotrophin signaling, Chemokine signaling path-
ways) as associated with RA. Furthermore, the KEGG
functional enrichment of drug target genes included these
terms.
3. Among the previously identified pathways, we identified
additional genes associated with RA (e.g. Antigen processing
and presentation, Tight junction). Importantly, within these
pathways, the associations between some of these additionally
found genes, such as HLA-C, HLA-G, PRKCQ, PRKCZ,
TAP1, TAP2 and RA were verified by either OMIM database
or by literature retrieved from the NCBI PubMed module.
4. Since our method can be easily applied to GWAS datasets of
other diseases, it will facilitate the identification of disease
specific pathways; and hence accelerate the development of
more specific and useful drugs with less side effects.
To conclude, our results show that incorporating SNP functional
properties, protein-protein interaction networks, pathway classifi-
cation tools into GWAS can dissect leading molecular pathways,
which cannot be picked up using traditional analyses. For GWAS
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mechanisms can only be identified by looking beyond the tip of the
iceberg (the most significant SNPs/genes). The development of
pathway and network-based approaches that also integrate prior
biologicalknowledgeforminingthe associationsof a groupof SNPs,
will take us one step closer to unravel the complex genetic structure
of common diseases.
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